mayo clinic glp-1 Are GLP-1s everything we hoped for? Primary Care in Rochester and

Lung function in idiopathic pulmonary fibrosis-extended analyses of the IFIGENIA trial

C., and Hoffman, R

This is particularly noteworthy because two competing oral small-molecule GLP-1 programs from Pfizer, lotiglipron (discontinued in 2023) and danuglipron (discontinued in April 2025), were terminated due to liver toxicity concerns

It is also one of the leading disabling conditions globally, accounting for nearly 47 million disability cases in 2019, and is expected to become the top global health problem by 2030 (17 Oct 2020, 2020

But what happens is when we're under chronic status and we're overworked and under recover, we're overfed, but we're actually malnourished because the soil is depleted or no longer mineral rich